# US 2018/0021273 A1 · Histone acetyltransferase activators and compositions and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0021273 A1
- Document ID: US20180021273A1
- Status: Published application
- Kind: A1
- Application number: 15/655,583
- Filed: 2017-07-20
- Published: 2018-01-25
- Earliest claimed: 2016-07-20
- Assignees: The Trustees of Columbia University in the City of New York
- Applicants: The Trustees of Columbia University In the City of New York
- Inventors: Owen Anthony O'CONNOR; Jennifer Effie AMENGUAL; Donald W. LANDRY; Ottavio ARANCIO; Luigi SCOTTO; Shi Xian DENG; Rosa PURGATORIO; Jole FIORITO
- Web page: https://patentgrep.com/patent/US20180021273A1

## CPC

- A61K 31/167: having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
- A61K 31/18: Sulfonamides (compounds containing a para-N-benzene-sulfonyl-N- group A61K31/63)
- A61K 31/381: having five-membered rings
- A61K 31/4035: Isoindoles, e.g. phthalimide
- A61K 31/44: Non condensed pyridines; Hydrogenated derivatives thereof
- A61K 31/4409: only substituted in position 4, e.g. isoniazid, iproniazid
- A61K 31/4453: only substituted in position 1, e.g. propipocaine, diperodon
- A61K 31/495: having six-membered rings with two {or more} nitrogen atoms as the only ring heteroatoms, e.g. piperazine {or tetrazines}(A61K31/48 takes precedence {; with three nitrogen atoms A61K31/53})
- A61K 31/505: Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K 31/535: having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 38/15: Depsipeptides; Derivatives thereof
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 21/02: Muscle relaxants, e.g. for tetanus or cramps
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/02: for peripheral neuropathies
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/20: Hypnotics; Sedatives
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 25/32: Alcohol-abuse
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 35/04: specific for metastasis
- A61P 39/02: Antidotes
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention provides pharmaceutical compositions and methods for treating cancer, neurodegenerative disorders, conditions associated with accumulated amyloid-beta peptide deposits, Tau protein levels, and/or accumulations of alpha-synuclein by administering a HAT modulator and a HDAC modulator to a subject.

## Claims

### Claim 1

A method for treating cancer in a subject in need thereof, the method comprising administering to a subject a HAT activator and a HDAC inhibitor.

### Claim 2 (depends on 1)

The method of claim 1, wherein the HAT activator is a compound of formula (I),
wherein,
Ar is
Ra is H, C1-C6-alkyl, C1-C6-haloalkyl, O—(C1-C6-alkyl), O—(C1-C6-haloalkyl), halogen, CN, or NO2;
Rb is H, OH, halogen, C1-C6-alkyl, —(C1-C6-alkyl)CO2—(C1-C6-alkyl), C1-C6-haloalkyl, C2-C6-alkenyl, C3-C8-cycloalkyl, C2-C6-heteroalkyl, C3-C8-heterocycloalkyl, aryl, heteroaryl, O—(C1-C6-alkyl), O—(C1-C6-alkyl)CO2—(C1-C6-alkyl), O—(C1-C6-haloalkyl), O—(C3-C8-cycloalkyl), O—(C2-C6-alkenyl), O—(C3-C8-heterocycloalkyl), N(R10)—(C1-C6-alkyl), N(R10)—(C1-C6-alkyl)CO2—(C1-C6-alkyl), N(R10)—(C3-C8-cycloalkyl), SH, S—(C1-C6-alkyl), S—(C1-C6-alkyl)CO2—(C1-C6-alkyl), SO2—(C1-C6-alkyl), SO2—(C1-C6-alkyl)CO2—(C1-C6-alkyl), O—(C2-C6-alkyl)-N(R10)2, O—(C2-C6-alkyl)-N(R10)3+halogen−, O—(C3-C8-cycloalkyl)-N(R10)2, N(R10)—(C2-C6-alkyl)-N(R10)2, —(C1-C6-alkyl)-N(R10)2, —(C1-C6-alkyl)-R3, O—(C1-C6-alkyl)-R3, O—(C3-C8-cycloalkyl)-R3, N(R10)—(C1-C6-alkyl)-R3, O-aryl, or O-heteroaryl;
Rc is H, —(C1-C6-alkyl), O—(C1-C6-alkyl), C(═O)NH-phenyl, wherein phenyl is substituted with one or more halo or haloalkyl;
Rd is H, OH, halogen, C1-C16-alkyl, C1-C16-haloalkyl, O—(C3-C8-cycloalkyl), O—(C3-C8-heterocycloalkyl), O—(C2-C6-alkenyl), O—(C1-C6-alkyl), O—(C1-C6-alkyl)-phenyl, O—(C2-C6-alkyl)-N(R10)2, O—(C2-C6-alkyl)-N(R10)3+halogen−, —(C1-C6-alkyl)-R3, O—(C1-C6-alkyl)-R3, O—S(C1-C6-alkyl), N(R10)—(C1-C6-alkyl)-R3, —N(R10)—(C1-C6-alkyl), —N(R10)—(C2-C6-alkenyl), —N(R10)—(C3-C8-cycloalkyl), —N(R10)—(C3-C8-heterocycloalkyl), N(R10)—(C2-C6-alkyl)-N(R10)2, —(C1-C6-alkyl)-N(R10)2, S—(C2-C6-alkyl)-N(R10)2, OCH2C(O)O(C1-C6-alkyl), O-aryl, N-aryl, O-heteroaryl, or N-heteroaryl;
U1-U4 are independently N or CRa, wherein U1-U4 are not each N;
V is a bond, N or CRc;
W and Z are independently N or CR1;
X is —CO—, —CON(R10)—, —CON(R10)(CH2)n—, —(CH2)nCON(R10)—, —(CH2)nCON(R10)(CH2)n—, —SON(R10)—, —SON(R10)(CH2)n—, —SO2N(R10)—, —SO2N(R10)(CH2)n—, —N(R10)C(═O)N(R10)—, —N(R10)CO—, —N(R10)CO(CH2)n—, or —N(R10)CO(CH2)n—, —(CH2)nN(R10)—, —C═N—; or
Ar and X together form
Y is a bond, N or CR2;
R1 is H, halogen, O—(C1-C6-alkyl), O—(C2-C6-alkyl)N(R10)2;
R2 is H, C1-C6-alkyl, C1-C6-haloalkyl, O—(C1-C6-alkyl), O—(C1-C6-haloalkyl), halogen, CN, or NO2;
R3 is cycloalkylamino, optionally containing a heteroatom selected from N(R10), O and S;
R10 is independently H, —(C1-C4-alkyl), —(C1-C4-haloalkyl), —(C3-C8-cycloalkyl), —(C3-C8-heterocycloalkyl), aryl or heteroaryl;
is a double bond and R11 is O, or
is a single bond and R11 is —(C1-C6-alkyl), —(C1-C6-alkyl)-N(R10)2, or —(C1-C6-alkyl)-N(R10)3+halogen−; and
each n is independently an integer from 1-4, or a pharmaceutically acceptable salt thereof.

### Claim 3 (depends on 1)

The method of claim 1, wherein the HAT activator is selected from the group consisting of
wherein R is H, Methyl, Ethyl, n-Propyl, Isopropyl, n-butyl, t-butyl, C8H18,C15H26, C15H28, C15H30, or C15H32.

### Claim 4 (depends on 1)

The method of claim 1, wherein the HAT activator is selected from the group consisting of
or a pharmaceutically acceptable salt thereof.

### Claim 5 (depends on 1)

The method of claim 1, wherein the HAT activator is selected from the group consisting of
or a pharmaceutically acceptable salt thereof.

### Claim 6

(canceled)

### Claim 7

(canceled)

### Claim 8 (depends on 1)

The method of claim 1, wherein the cancer comprises B cell lymphoma, colon cancer, lung cancer, renal cancer, bladder cancer, T cell lymphoma, myeloma, leukemia, chronic myeloid leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, acute lymphocytic leukemia, hematopoietic neoplasias, thymoma, lymphoma, sarcoma, lung cancer, liver cancer, non-Hodgkin's lymphoma, Hodgkin's lymphoma, uterine cancer, renal cell carcinoma, hepatoma, adenocarcinoma, breast cancer, pancreatic cancer, liver cancer, prostate cancer, head and neck carcinoma, thyroid carcinoma, soft tissue sarcoma, ovarian cancer, primary or metastatic melanoma, squamous cell carcinoma, basal cell carcinoma, brain cancer, angiosarcoma, hemangiosarcoma, bone sarcoma, fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, testicular cancer, uterine cancer, cervical cancer, gastrointestinal cancer, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, Waldenstroom's macroglobulinemia, papillary adenocarcinomas, cystadenocarcinoma, bronchogenic carcinoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilms' tumor, lung carcinoma, epithelial carcinoma, cervical cancer, testicular tumor, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, meningioma, retinoblastoma, leukemia, melanoma, neuroblastoma, small cell lung carcinoma, bladder carcinoma, multiple myeloma, follicular lymphoma or medullary carcinoma.

### Claim 9 (depends on 1)

The method of claim 1 wherein the HAT activator increases histone acetylation.

### Claim 10 (depends on 1)

The method of claim 1, wherein the HDAC inhibitor increases histone acetylation.

### Claim 11 (depends on 9)

The method of claim 9, wherein histone acetylation comprises acetylation of histones H12B, 1-13, 1-14, or a combination thereof.

### Claim 12 (depends on 9)

The method of claim 9, wherein histone acetylation comprises acetylation of histone lysine residues H3K4, H3K9, H3K14, H4K5, H4K8, H4K12, H4K16, or a combination thereof.

### Claim 13 (depends on 1)

The method of claim 1, wherein the HAT activator increases p53 acetylation.

### Claim 14 (depends on 1)

The method of claim 1, wherein the HDAC inhibitor increases p53 acetylation.

### Claim 15 (depends on 1)

The method of claim 1, wherein the HDAC inhibitor is romidepsin, vorinostat, belinostat, panobinostat, entinostat, mocetinostat, abexinostat, quisinostat or gavinostat.

### Claim 16 (depends on 1)

The method of claim 1, wherein the HDAC inhibitor is romidepsin or vorinostat.

### Claim 17 (depends on 1)

The method of claim 1, wherein the HDAC inhibitor is romidepsin.

### Claim 18 (depends on 1)

The method of claim 1, wherein the HDAC inhibitor is chidamide, resminostat, givinostat, or kevetrin.

### Claim 19 (depends on 1)

The method of claim 1, wherein the cancer is colon cancer, lung cancer, renal cancer, leukemia, CNS cancer, melanoma, ovarian cancer, breast cancer, or prostate cancer.

### Claim 20 (depends on 1)

The method of claim 1, wherein the cancer is colon cancer, renal cancer, T cell leukemia, myeloma, leukemia, acute myeloid leukemia, acute lymphocytic leukemia, renal cell carcinoma, adenocarcinoma, glioblastoma, breast carcinoma, prostate carcinoma, or lung carcinoma.

### Claim 21 (depends on 1)

The method of claim 1, wherein the cancer is Hodgkin's lymphoma, non-Hodgkin's lymphoma, B cell lymphoma, T cell lymphoma, or follicular lymphoma.

### Claim 22 (depends on 1)

The method of claim 1, wherein the B cell lymphoma is diffuse large B-cell lymphoma.

### Claim 23 (depends on 22)

The method of claim 22, wherein the diffuse large B-cell lymphoma is a germinal center-derived diffuse large B cell lymphoma, an activated B-cell-derived (ABC) diffuse large B-cell lymphoma, or non-germinal center diffuse large B cell lymphoma.

### Claim at position 24

24-34. (canceled)

### Claim 35 (depends on 1)

The method of claim 1, wherein the subject has at least one mutant HAT enzyme gene.

### Claim 36 (depends on 1)

The method of claim 1, wherein the subject has a wildtype EP300 and wildtype CREBBP gene.

### Claim 37 (depends on 1)

The method of claim 1, wherein the subject has a wildtype EP300 and CREBBP mutant gene.

### Claim 38 (depends on 37)

The method of claim 37, wherein the mutation is on only one allele of EP300.

### Claim 39 (depends on 1)

The method of claim 1, wherein the subject has a mutant EP300 and CREBBP wildtype gene.

### Claim 40 (depends on 39)

The method of claim 39, wherein the mutation is on only one allele of EP300.

### Claim 41 (depends on 1)

The method of claim 1, wherein the subject has a mutant EP300 and CREBBP mutant gene.

### Claim 42 (depends on 41)

The method of claim 41, wherein the mutation is on only one allele of EP300 and on only one allele of CREBBP.

### Claim 43

(canceled)

### Claim 44

(canceled)

### Claim 45 (depends on 35)

The method of claim 35, wherein the HAT activator is
or a pharmaceutically acceptable salt thereof.

### Claim 46 (depends on 35)

The method of claim 35, wherein the HAT activator is
or a pharmaceutically acceptable salt thereof.

### Claim 47 (depends on 46)

The method of claim 46, wherein the HDAC inhibitor is romidepsin.

### Claim 48

A pharmaceutical composition comprising a HAT activator and a HDAC inhibitor.

### Claim 49 (depends on 48)

The pharmaceutical composition of claim 48, wherein the HAT activator has a structure of formula (I),
wherein,
Ar is
Ra is H, C1-C6-alkyl, C1-C6-haloalkyl, O—(C1-C6-alkyl), O—(C1-C6-haloalkyl), halogen, CN, or NO2;
Rb is H, OH, halogen, C1-C6-alkyl, —(C1-C6-alkyl)CO2—(C1-C6-alkyl), C1-C6-haloalkyl, C2-C6-alkenyl, C3-C8-cycloalkyl, C2-C6-heteroalkyl, C3-C8-heterocycloalkyl, aryl, heteroaryl, O—(C1-C6-alkyl), O—(C1-C6-alkyl)CO2—(C1-C6-alkyl), O—(C1-C6-haloalkyl), O—(C3-C8-cycloalkyl), O—(C2-C6-alkenyl), O—(C3-C8-heterocycloalkyl), N(R10)—(C1-C6-alkyl), N(R10)—(C1-C6-alkyl)CO2—(C1-C6-alkyl), N(R10)—(C3-C8-cycloalkyl), SH, S—(C1-C6-alkyl), S—(C1-C6-alkyl)CO2—(C1-C6-alkyl), SO2—(C1-C6-alkyl), SO2—(C1-C6-alkyl)CO2—(C1-C6-alkyl), O—(C2-C6-alkyl)-N(R10)2, O—(C2-C6-alkyl)-N(R10)3+halogen−, O—(C3-C8-cycloalkyl)-N(R10)2, N(R10)—(C2-C6-alkyl)-N(R10)2, —(C1-C6-alkyl)-N(R10)2, —(C1-C6-alkyl)-R3, O—(C1-C6-alkyl)-R3, O—(C3-C8-cycloalkyl)-R3, N(R10)—(C1-C6-alkyl)-R3, O-aryl, or O-heteroaryl;
Rc is H, —(C1-C6-alkyl), O—(C1-C6-alkyl), C(═O)NH-phenyl, wherein phenyl is substituted with one or more halo or haloalkyl;
Rd is H, OH, halogen, C1-C16-alkyl, C1-C16-haloalkyl, O—(C3-C8-cycloalkyl), O—(C3-C8-heterocycloalkyl), O—(C2-C6-alkenyl), O—(C1-C6-alkyl), O—(C1-C6-alkyl)-phenyl, O—(C2-C6-alkyl)-N(R10)2, O—(C2-C6-alkyl)-N(R10)3+halogen−, —(C1-C6-alkyl)-R3, O—(C1-C6-alkyl)-R3, O—S(C1-C6-alkyl), N(R10)—(C1-C6-alkyl)-R3, —N(R10)—(C1-C6-alkyl), —N(R10)—(C2-C6-alkenyl), —N(R10)—(C3-C8-cycloalkyl), —N(R10)—(C3-C8-heterocycloalkyl), N(R10)—(C2-C6-alkyl)-N(R10)2, —(C1-C6-alkyl)-N(R10)2, S—(C2-C6-alkyl)-N(R10)2, OCH2C(O)O(C1-C6-alkyl), O-aryl, N-aryl, O-heteroaryl, or N-heteroaryl;
U1-U4 are independently N or CRa, wherein U1-U4 are not each N;
V is a bond, N or CRc;
W and Z are independently N or CR1;
X is —CO—, —CON(R10)—, —CON(R10)(CH2)n—, —(CH2)nCON(R10)—, —(CH2)nCON(R10)(CH2)n—, —SON(R10)—, —SON(R10)(CH2)n—, —SO2N(R10)—, —SO2N(R10)(CH2)n—, —N(R10)C(═O)N(R10)—, —N(R10)CO—, —N(R10)CO(CH2)n—, or —N(R10)CO(CH2)n—, —(CH2)nN(R10)—, —C═N—; or
Ar and X together form
Y is a bond, N or CR2;
R1 is H, halogen, O—(C1-C6-alkyl), O—(C2-C6-alkyl)N(R10)2;
R2 is H, C1-C6-alkyl, C1-C6-haloalkyl, O—(C1-C6-alkyl), O—(C1-C6-haloalkyl), halogen, CN, or NO2;
R3 is cycloalkylamino, optionally containing a heteroatom selected from N(R10), O and S;
R10 is independently H, —(C1-C4-alkyl), —(C1-C4-haloalkyl), —(C3-C8-cycloalkyl), —(C3-C8-heterocycloalkyl), aryl or heteroaryl;
is a double bond and R11 is O; or
is a single bond and R11 is —(C1-C6-alkyl), —(C1-C6-alkyl)-N(R10)2, or —(C1-C6-alkyl)-N(R10)3+halogen; and
each n is independently an integer from 1-4, or a pharmaceutically acceptable salt thereof.

### Claim 50 (depends on 48)

The pharmaceutical composition of claim 48, wherein the HAT activator is selected from the group consisting of:
wherein R is H, Methyl, Ethyl, n-Propyl, Isopropyl, n-butyl, t-butyl, C8H18,C15H26, C15H28, C15H30, or C15H32.

### Claim 51 (depends on 48)

The pharmaceutical composition of claim 48, wherein the HAT activator is selected from the group consisting of:
or a pharmaceutically acceptable salt thereof.

### Claim 52 (depends on 48)

The pharmaceutical composition of claim 48, wherein the HAT activator is selected from the group consisting of:
or a pharmaceutically acceptable salt thereof.

### Claim 53 (depends on 48)

The pharmaceutical composition of claim 48, wherein the HAT activator is
or a pharmaceutically acceptable salt thereof.

### Claim 54 (depends on 48)

The pharmaceutical composition of claim 48, wherein the HAT activator is
or a pharmaceutically acceptable salt thereof.

### Claim 55 (depends on 54)

The pharmaceutical composition of claim 54, wherein the HDAC inhibitor is romidepsin.
